Cardiac Vascular News – The best place for the Latest Cardiac and Vascular News

Coronary/Structural Heart

JenaValve Technology Implants Initial Patients in CE Mark Study for the Treatment of Severe Aortic Regurgitation with Next-Generation TAVR System

June 19, 2018 0 comments

IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment and implantations associated with the CE Mark study of its next generation JenaValve Pericardial TAVR System using the CoronatixTM Transfemoral Delivery Catheter for the percutaneous treatment of patients […]

IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack Damage

June 19, 2018 0 comments

HOUSTON–(BUSINESS WIRE)–IPS HEART, resident of Johnson & Johnson Innovation, JLABS is pioneering the use of IPS cellular therapy for the replacement of heart tissue after heart attack, heart failure and duchenne cardiomyopathy. Recent results were presented at the 82nd Annual Scientific Meeting of the Japanese Circulation Society showing over 66% […]

Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

June 19, 2018 0 comments

BASKING RIDGE, N.J., June 19, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces today that the U.S. Food and Drug Administration (“FDA”) has granted regenerative medicine advanced therapy (“RMAT”) designation to […]

Interviews/Contributions

The Modernization of Carotid Repair to Reduce the Risk of Stroke

May 18, 2018 0 comments

Contributed by Steve Henao, MD A very pleasant, active 75-year-old patient at our hospital received the disturbing news last July that she had an 80 percent blockage in one of her two carotid arteries, a diagnosis known as carotid artery disease. She was concerned about the risk of treatment and […]

Other News

Corindus Promotes Doug Teany to Chief Operating Officer

Financial June 19, 2018 by Ken Dropiewski 0 comments

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that it has appointed Douglas Teany, currently the company’s Senior Vice President of R&D and Operations, to Chief Operating Officer, effective immediately. Teany brought eighteen years of experience to Corindus, driving operational excellence […]

Continue Reading →

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

Financial June 19, 2018 by Ken Dropiewski 0 comments

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson MD, PhD has been appointed President and Chief Executive Officer. Carrie S. Cox has assumed the role of Executive Chairman. Dr. Lawson, an innovator, scientist and vascular surgeon has been involved in the […]

Continue Reading →

FEops Strengthens Management Team

Financial June 19, 2018 by Ken Dropiewski 0 comments

GENT, Belgium–(BUSINESS WIRE)–FEops, the leader in personalized computational modeling and simulation for structural heart interventions, today announced the expansion of its management team with the appointments of Christian Vincent as Director of Therapy Development and Nico Uwents as Director of Business Development. “Both Christian and Nico have a long track record of success in […]

Continue Reading →

IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack Damage

Coronary/Structural Heart June 19, 2018 by Ken Dropiewski 0 comments

Continue Reading →

Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

Coronary/Structural Heart Regulatory June 19, 2018 by Ken Dropiewski 0 comments

Continue Reading →

Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

Coronary/Structural Heart June 19, 2018 by Ken Dropiewski 0 comments

VALENCIA, SPAIN., June 19, 2018 (GLOBE NEWSWIRE) — Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its […]

Continue Reading →

Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting

Peripheral/Endo June 19, 2018 by Ken Dropiewski 0 comments

SUNNYVALE, Calif.–(BUSINESS WIRE)–Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced key events at the upcoming Society for Vascular Surgery 2018 Vascular Annual Meeting (VAM) June 20-23 at the Hynes Convention Center in Boston. These include real-world data presentations comparing […]

Continue Reading →

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018

Rhythm June 19, 2018 by Ken Dropiewski 0 comments

MENLO PARK, Calif.–(BUSINESS WIRE)–BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Transcatheter Valve Therapies (TVT) structural heart disease summit, which will take place June 20-22 at the Sheraton Grand Chicago. The company’s Tempo® Temporary Pacing Lead will be featured in a […]

Continue Reading →

AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug

Peripheral/Endo Regulatory June 19, 2018 by Ken Dropiewski 0 comments

HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) — AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™, through the FDA approval process. The regulatory firm will begin with a presubmission meeting with the FDA biologic group […]

Continue Reading →

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

Rhythm June 19, 2018 by Ken Dropiewski 0 comments

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) — Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today announced that Columbia University (“Columbia”) will present a complete analysis of cardiac data from the Phase 1b trial of CAEL-101 (mAb 11-1F4) for the […]

Continue Reading →

Featured

JenaValve Technology Implants Initial Patients in CE Mark Study for the Treatment of Severe Aortic Regurgitation with Next-Generation TAVR System

IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack Damage

Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting

AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug

Top Stories

Corindus Promotes Doug Teany to Chief Operating Officer

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

FEops Strengthens Management Team

Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug

FDA Advisory Committee Votes in Favor of Cardinal Health’s INCRAFT® AAA Stent Graft System for the Endovascular Treatment of Infrarenal Abdominal Aortic Aneurysms

LivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring

LivaNova Welcomes William Kozy to Board of Directors

Avinger Appoints Mark Weinswig as Chief Financial Officer

Shifamed Announces $15.5M Series A Financing

Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting

AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug

Microbot Medical Inc. Announces European Patent Office’s Intent to Grant Patent for Device for the Prevention of Shunt Stenosis

Corindus Promotes Doug Teany to Chief Operating Officer

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

FEops Strengthens Management Team

Recent

JenaValve Technology Implants Initial Patients in CE Mark Study for the Treatment of Severe Aortic Regurgitation with Next-Generation TAVR System

Corindus Promotes Doug Teany to Chief Operating Officer

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive Officer

FEops Strengthens Management Team

IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack Damage

Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting

BioTrace Medical Announces Key Events Featuring Tempo® Lead at TVT 2018

AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug

Other News

Recent

Popular

Subscribe to Blog via Email

The Modernization of Carotid Repair to Reduce the Risk of Stroke